Fifty-seventh annual meeting of the American association of physicists in medicine
SU-E-T-353: Effects of Time and Temperature On a Potential Reusable 3D Dosimeter
Preliminary studies of a novel, optically-clearing PRESAGE 3D dosimeter formulation (Presage-RU) demonstrated potential reusability. This study investigates the effects of time and temperature on the accuracy and reusability of Presage-RU, and reports on progress toward developing a reusable 3D dosimeter.
Presage-RU was cast as small volume samples (1×1×4.5cm). The effect of dose response sensitivity with reirradiation and time was evaluated by irradiating samples from 0–10Gy, measuring change in optical density (ΔOD), clearing at room temperature (RT) (5–7 days to fully clear), and then repeating for a total of 5 irradiations. Effects of heating on clearing rate were investigated by irradiating samples to 8Gy, then tracking measurements with samples held at RT, 35°C, and 45°C. Two cylindrical dosimeters (11cm diameter, 9.5cm length) were evaluated for dosimetric accuracy when stored at RT and −3°C prior to irradiation. Plans delivered were 2 overlapping AP fields (RT) and VMAT (-3°C).
Heating the dosimeters reduced the clearing half-life from 16.3h at RT to 5.8h (35°C) and 5.1h (45°C), but also increased background ΔOD by 1.7x (35°C) and 2.3x (45°C). Reductions in dose response were more closely linked to age than reirradiation, and storage at RT showed pronounced desensitization from dosimeter edges. These results suggest desensitization from oxygen diffusion. It should be noted that atmospheric diffusion into the dosimeter is not seen in standard, single-use PRESAGE, and is likely caused by differences in the Presage-RU polyurethane matrix. The dosimeter kept in cold storage, however, showed no evidence of desensitization and exhibited accuracy on par with standard PRESAGE with a 3%/3mm 3D gamma passing rate of 98.1%.
Presage-RU is sensitive to storage temperatures and time, both of which affect oxygen diffusion and subsequent desensitization. Development shows promising progress with further formulation optimization as the next step toward achieving a successful reusable 3D dosimeter.
This work was supported by NIH R01CA100835. John Adamovics is the president of Heuris Inc., which commercializes PRESAGE.